Six pharmaceutical mergers and acquisitions this month Fosun built a $1 billion API base

This month, six pharmaceutical mergers and acquisitions, Fosun 1 billion to build a raw materials base.The state-owned enterprises 2 billion real control of Hainan Hai Medicine
recently, Hainan Hai Medicine announcement shows that: November 16, 2018, Hainan Hai Medicine received the company's controlling shareholder Shenzhen Southern Tongzheng Investment "notice letter."
in order to promote the long-term sustainable development of the company, Mr. Liu Shicheng, the de facto controller of Southern Tongzheng Company, and his spouse, Ms. Qiu Xiaowei, signed the Cooperation Framework Agreement with Emerging Inter-China Pharmaceutical Holdings (Party A).
Emerging Inter-China Pharmaceuticals intends to gain control of Hainan Hai Medicine through a cash-for-capital increase of up to 2 billion yuan.
it is learned that Emerging Inter-China Pharmaceuticals is a wholly-owned secondary subsidiary of Emerging Inter-China Group Co., Ltd., a large central enterprise directly supervised by the State-owned Assets Supervision and Administration Commission of the State Council, and is the business platform of the pharmaceutical sector of the Emerging Inter-China Group Corporation.according to the
announcement, the acquisition intention of Emerging Inter-China Pharmaceuticals is mainly to implement the major strategic layout of emerging industries in which Emerging Inter-China Group Companies enter the frontiers of "Made in China 2025" and build the emerging industries to which global talents as yearn, and to acquire listed pharmaceutical companies as a platform for their industrial development and capital market operation.
if the deal is successful, Hainan Hai medicine could become a platform for industrial integration in the pharmaceutical industry such as chemical innovation drugs, biotechnology pharmaceuticals and high-end medical devices.Nearly 400 Acquisitions of Shanghai Les History
On November 22nd, Shanghai Raith announced its proposed acquisition of Biostest, a global chain-wide blood products company, and GDS, the world's leading manufacturer of blood testing equipment.
Announced that the underlying assets of this major asset restructuring were originally 100% of Tiancheng International's core assets are Bio Products Laboratory Holdings Limited ("BPL") and Tiancheng ("Germany") Pharmaceutical Holdings AG ("Germany"), wholly owned subsidiaries of Biotest AG ("Biotest").
all of the plasma stations held by the BPL are located in the United States, and due to the recent trade tensions between the United States and China, the BPL's declaration of the CFIUS review has been slow to reach a clear conclusion and the uncertainty of its ability to pass the review is high.
, in order to safeguard the interests of listed companies and shareholders, the Company intends to temporarily abandon the acquisition of BPL and continue to acquire Biost.
Based on the preliminary negotiations between the listed company and the other party, Tiancheng Germany's 100% stake is proposed to be worth about 589 million euros (4.8 billion yuan), GDS 100% is proposed to be worth about 5 billion U.S. dollars (34.3 billion yuan), and the final transaction price is to be assessed/valued by an assessment body qualified for securities practice and determined by the relevant parties.
, Biotest is a global, industry-wide blood products company with 70 years of experience in the manufacture of blood products, with biotest headquartered in Dreich, Hesse, Germany, according to the company. In 1987, Biotest shares were listed on the Frankfurt Stock Exchange in Germany.
GDS is the world's leading manufacturer of blood testing equipment, whose main business is nucleic acid detection, immunoantigen and blood type testing in blood transfusion medicine.To sell a pharmaceutical company
On November 27th, State Pharmaceuticals issued an "announcement on receipt of a letter of commitment from the company's actual controller" and plans to sell one of its pharmaceutical companies.
announcement shows that recently, China Pharmaceutical Group Pharmaceutical Co., Ltd. received the actual controller of China Pharmaceutical Group Co., Ltd. issued a letter of commitment, the main content of the letter of commitment is as follows:
from the date of the commitment to issue five years, will promote The State Pharmaceutical Holdings, China Pharmaceuticals shares through including but not limited to the choice of machine to inject Guorui Pharmaceuticals into modern pharmaceutical, the sale of Guorui Pharmaceuticals to an independent third party without a related relationship, adjust the structure of Guorui Pharmaceutical products and other ways to dispose of.
, that is to say, The Swiss Pharmaceuticals will be sold within five years.
, according to public information, Guorui Pharmaceuticals, formerly named Huainan City, the sixth pharmaceutical factory, was founded in 1986. In 1998, he joined China Pharmaceutical (Group) Co., Ltd. in the form of a total allocation, and changed its name to Guorui Pharmaceutical Co., Ltd., a national pharmaceutical group.
focus on the production and operation of chemicals, focusing on cardiovascular drugs, anti-infective drugs, cancer drugs, respiratory drugs in the four major therapeutic areas of pharmaceutical preparations and their supporting raw materials.
has more than 160 varieties, specifications of product approval number, including freeze-dried powder needles, powder needles (including cephalosporins), small-capacity injections, oral solid preparations, RAW drugs., China Pearl Medical Co., Ltd.
On Nov. 1, Zhongzhu Medical issued a supplementary announcement on the acquisition of a 60% stake in Ci Xiang Pharmaceuticals by its controlling subsidiary, Sunjiang Pharmaceuticals.
It was announced that on October 30, 2018, Sunjiang Pharmaceuticals signed an Equity Transfer Agreement to acquire a 39% stake in Ci xiang Pharmaceuticals and a 21% stake in Ci xiang Pharmaceuticals held by Xiong Jie for a total price of RMB 5 million.
is understood that Sunjiang Pharmaceuticals holds a 40% stake in Ci xiang Pharmaceuticals, Huadan Pharmaceuticals holds a 39% stake in Ci xiang Pharmaceuticals and Xiong Jie holds a 21% stake in Ci xiang Pharmaceuticals.
if the transaction is completed, Ci xiang Pharmaceutical's equity structure is: Submarine Pharmaceuticals holds a 100% stake.
According to the announcement, Ci Xiang Pharmaceuticals is a pharmaceutical production enterprise mainly used in other pharmaceutical preparations, mainly engaged in ear preparations, nasal preparations, suppositions, antidotes, enema coating production, wholesale, retail and so on. At present, has obtained the drug GMP certificate, drug production license, design patent certificate.Xinhua Pharmaceuticals Holdings Change
On November 26, Xinhua Pharmaceuticals announced that Hualu Group would be subject to 32.94 percent of Xinhua Pharmaceuticals' total share capital held by Xinhua Group.
that Hualu Group mainly invests in chemical, pharmaceutical and environmental protection industries (industries) with its own funds;
In accordance with the deployment requirements of SASAC in Shandong Province, in order to promote the comprehensive deepening of reform of state-owned enterprises, further reduce the management level and improve management efficiency, Hualu Group intends to absorb the merger of Xinhua Group, resulting in its transfer of Xinhua Group's holding of 204864092 shares of Xinhua Pharmaceuticals A-shares, accounting for 32.94 percent of Xinhua Pharmaceutical's total share capital.
the completion of the merger, the controlling shareholder of Xinhua Pharmaceuticals changed to Hualu Group, the actual controller remains unchanged, still the SASAC of Shandong Province.East China Pharmaceuticals' $1.52 billion acquisition completed
On November 8, East China Pharmaceuticals announced that East China Pharmaceuticals and Sinclair Pharma plc ("Sinclair") had made an official offer to acquire all of Sinclair's shares through a cash offer on the London Stock Exchange on September 18, 2018.
under the cash offer, the offer is priced at 32 pence per share, and the total value of the acquisition of sinclair's total shares is approximately ￡169 million (approximately RMB1.52 billion at current exchange rates).
as of this announcement date, sinclair's entire share has been owned by The Company's whon-owned Sun Company, East China Medical Andy, and the Company's cash offer to acquire all of Sinclair's shares has been completed.
According to the announcement, Sinclair, headquartered in London, UK, is a leading global medical and aesthetic company with a global presence, covering the entire industrial chain of research and development, production and sales, the technical advantages of its products, brand influence, market position and future growth potential, as well as an international management and operations team of more than 200 people.
addition to mergers and acquisitions between pharmaceutical companies, pharmaceutical companies launched new businesses in November. Fosun 1 billion to build a raw materials base
On November 27, Shanghai Fosun Pharmaceuticals announced that it had agreed to invest no more than 1 billion yuan in a holding subsidiary, Chongqing Pharmaceuticals Pharmaceuticals, in the "International Industrial Base of RAW Drugs".
On October 24, 2017, Chongqing Pharmaceuticals Pharmaceutical Co., Ltd., a controlling subsidiary of Shanghai Fosun Pharma (Group) Co., Ltd., signed a Strategic Cooperative Investment Agreement with the Management Committee of Changde Economic and Technological Development Zone in Hunan Province, reaching a consensus on the investment and construction of API bases by Chongqing Pharmaceutical Friends in Changde Economic and Technological Development Zone, Hunan Province.
November 27, 2018, after consideration by the 75th Board of Directors of Shanghai Fosun, it was agreed that Chongqing Pharmaceutical Friends and/or its controlling subsidiaries should invest no more than RMB 1 billion in the first phase of the construction of an "International Industrial Base for API" in Changde's Economic Zone.
announced that the construction project is mainly combined with the relocation and industrial upgrading of Chongqing Pharmaceutical Friends Holdings subsidiary implementation, aimed at integrating API production resources, improve the production chain.
the construction of the API base in accordance with international standards, the construction project will become the API production base of Chongqing Pharmaceutical Friends and its controlling subsidiaries, as well as the supply of API for external preparation production enterprises. (Seber Blue Synthesis)